Who’s on First? Case Report on Prioritizing Treatment for Comorbid Attention-Deficit/Hyperactivity and Anxiety Disorders

Main Article Content

Kelly C. Lee, Pharm.D., MAS, BCPP Natasha Bilinsky Jamie Kneebusch, Pharm.D., BCPS, BCPP

Abstract

Early and optimal treatment of attention-deficit/hyperactivity disorder (ADHD) has been shown to prevent comorbid conditions. Unfortunately, due to delayed diagnosis or treatment of ADHD, psychiatric comorbidities often emerge that can also result in more disabling symptoms. Stimulants remain the gold standard for treatment of ADHD whereas serotonergic antidepressants are first line for anxiety disorders. Treatment of patients with ADHD and anxiety disorders presents a clinical conundrum due to the potential for stimulants to worsen anxiety symptoms. Many clinicians may defer treating ADHD initially and treating the anxiety disorder first. Unfortunately, untreated ADHD may worsen anxiety symptoms and expose patients to long-term treatment with anxiolytics that may be unnecessary. In this Clinical Case Discussion, we present the clinical and pathophysiological overlap between ADHD and anxiety disorders along with a clinical case. We present how a complete evaluation of the patient, including disturbance of symptoms on functioning and symptom onset, may help prioritize treatment strategies. Despite the reluctance to prescribe stimulants especially to adults due to stimulant misuse and exacerbation of other disorders, it may be optimal to treat ADHD first in order to reduce other manifestations.

Keywords: attention-deficit, hyperactivity, ADHD, anxiety, insomnia

Article Details

How to Cite
LEE, Kelly C.; BILINSKY, Natasha; KNEEBUSCH, Jamie. Who’s on First? Case Report on Prioritizing Treatment for Comorbid Attention-Deficit/Hyperactivity and Anxiety Disorders. Medical Research Archives, [S.l.], v. 12, n. 10, oct. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5906>. Date accessed: 03 dec. 2024. doi: https://doi.org/10.18103/mra.v12i10.5906.
Section
Case Reports

References

1. Oliva F, Malandrone F, Mirabella S, Ferreri P, di Girolamo G, Maina G. Diagnostic delay in ADHD: Duration of untreated illness and its socio-demographic and clinical predictors in a sample of adult outpatients. Early Interv Psychiatry 2021;15(4):957-965. Doi: 10.1111/eip.13041.
2. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry 2017;17(1):302. Doi: 10.1186/s12888-017-1463-3.
3. Quenneville AF, Kalogeropoulou E, Nicastro R, Weibel S, Chanut F, Perroud N. Anxiety disorders in adult ADHD: A frequent comorbidity and a risk factor for externalizing problems. Psychiatry Res 2022;310:114423. Doi:10.1016/j.psychres.2022.114423.
4. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006;256 Suppl 1:i26-31. Doi: 10.1007/s00406-006-1004-4.
5. Generalized Anxiety Disorder. National Institute of Mental Health. Available: https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder#:~:text=Prevalence%20of%20Generalized%20Anxiety%20Disorder%20Among%20Adults,-Based%20on%20diagnostic&text=An%20estimated%205.7%25%20of%20U.S.,some%20time%20in%20their%20lives. Accessed September 24, 2024.
6. Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care. Prim Care Companion J Clin Psychiatry 2007;9(2):129-38.
7. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 2012;10:99. Doi: 10.1186/1741-7015-10-99.
8. Murray AL, Caye A, McKenzie K, et al. Reciprocal developmental relations between ADHD and anxiety in adolescence: a within-person longitudinal analysis of commonly co-occurring symptoms. J Atten Disord 2022;26(1):109-118. Doi:10.1177/1087054720908333.
9. Baldwin JS, Dadds MR. Examining alternative explanations of the covariation of ADHD and anxiety symptoms in children: a community study. J Abnorm Child Psychol 2008;36(1):67-79. Doi:10.1007/s10802-007-9160-1.
10. Becker SP, Luebbe AM, Stoppelbein L, Greening L, Fite PJ. Aggression among children with ADHD, anxiety, or co-occurring symptoms: competing exacerbation and attenuation hypotheses. J Abnorm Child Psychol 2012;40(4):527-42. Doi:10.1007/s10802-011-9590-7.
11. Jarrett MA, Wolff JC, Davis TE, 3rd, Cowart MJ, Ollendick TH. Characteristics of children with adhd and comorbid anxiety. J Atten Disord 2016;20(7):636-44. Doi:10.1177/1087054712452914.
12. Jensen CM, Amdisen BL, Jorgensen KJ, Arnfred SM. Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Atten Defic Hyperact Disord 2016;8(1):3-11. Doi: 10.1007/s12402-016-0188-3.
13. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009;124(1):71-8. Doi:10.1542/peds.2008-3347.
14. The ADHD Diagnostic Process. Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). Available: https://chadd.org/for-professionals/the-adhd-diagnostic-process/#:~:text=The%20interview%20should%20include%20a,situations%20or%20the%20same%20one%3F. Accessed September 8, 2024.
15. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Children and Adults with Attention-Deficity/Hyperactivity Disorder (CHADD). Available: https://chadd.org/for-professionals/clinical-practice-guidelines/. Accessed September 8, 2024.
16. Khoodoruth MAS, Ouanes S, Khan YS. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder. Res Dev Disabil 2022;128:104275. Doi: 10.1016/j.ridd.2022.104275.
17. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007;46(9):1119-1127. Doi:10.1097/chi.0b013e3180ca8385.
18. Hvolby A. Associations of sleep disturbance with ADHD: implications for treatment. Atten Defic Hyperact Disord 2015;7(1):1-18. Doi:10.1007/s12402-014-0151-0.
19. Heissel A, Heinen D, Brokmeier LL, et al. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. Br J Sports Med 2023;57(16):1049-1057. Doi:10.1136/bjsports-2022-106282.
20. Leon-Barriera R, Ortegon RS, Chaplin MM, Modesto-Lowe V. Treating ADHD and Comorbid Anxiety in Children: A Guide for Clinical Practice. Clin Pediatr (Phila) 2023;62(1):39-46. Doi:10.1177/00099228221111246.